Revance Therapeutics, a Mountain View biopharmaceutical company developing topical skin aging treatments, has secured almost $4 million in funding through convertible securities, according to a filing with the Securities and Exchange Commission cited by VentureWire (sub required):
Institutional investors listed on the filing include Niagara Gorge Venture Partners LLC, Biotechnology Development Fund, Essex Woodlands Health Ventures and Technology Partners. The actual amount raised by the company in this funding is more than $4 million, according to a person close to the deal. The company may look to take in a Series C funding later this year, the person also said.
(First posted 2/22)